who invented glp-1 drugs made for US': Medanta founder Dr. Naresh Trehan explains risks for Indians using weight-loss Her work paved the way

The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes

You can wear multiple PatchAid patches at the same time

In addition, this report is a consensus of expert endocrinologists representing South Asian countries including India, Pakistan, Bangladesh, Nepal, Sri Lanka, Afghanistan and the Maldives on essential recommendations related to the use of GLP-1 RAs in a real-world scenario.

Semaglutide is the start of a new chapter in obesity treatments.

Method The PubMed (MEDLINE), EMBASE, Cochrane Library, and ClinicalTrials.gov databases were searched from the establishment of the database to December 24, 2022

Conclusions Our initial data suggest that GLP-1 RA use does not lead to substantial gastric food retention as observed in EGDs